



**Alliance for Clinical Trials in Oncology**  
**Thursday, November 5, 2015**  
**Loews Chicago O'Hare Hotel**  
**2:30 pm – 7 pm**

**Leukemia/Leukemia Correlative Sciences Committees**  
**Meeting Agenda**

Chairs: Richard M. Stone, MD and John C. Byrd, MD  
 Vice-Chairs: Guido Marcucci MD (LC), MD; Tom Shea, MD (LC); and  
 Wendy Stock, MD, PhD ( LC/LCS)

	<b>Introduction</b>
	Richard Stone MD (230-240)
	<b>Update: Leukemia Correlative Sciences</b>
	John Byrd, MD (240-250)
	<b>Statistics and Data Management</b>
	Sumithra Mandrekar, PhD, et al (250-300)
	<b>ASH abstract; CALGB 10002; Soraf in older AML FLT3 mut</b>
	Geoff Uy MD (300-315)
	<b>Update on WHO classification AML</b> <b>ASH abstract; CALGB 10603; Mido v PL younger AML FLT3 mut</b>
	Rich Stone, MD (320-340)
	<b>Promoting apoptosis in AML</b>
	Tony Letai, MD, PhD (340-400)

Protocol Review				
Category	Study Title	Study Number	Study Chair	Presenter's Name
Active	Chemo +/- blinatumumab in middle aged adults with pre-B-ALL	E1910	M. Litzow M. Wieduwilt, (A)	M. Wieduwilt (4-410)
In Development	PH+ ALL working groups concepts, incl S0805 and C01701			K. Jamieson M. Wieduwilt (410-425)
In development	Ph III successor to 10403:		D. DeAngelo	D. DeAngelo (425-435)
In Development	Anclary Science/AYA study		W. Stock	W. Stock (435-445)
CTEP Approved	Blinatumumamab plus POMP in PH- ALL, age >70	S1318	A. Advani M. Wieduwilt (A)	M. Wieduwilt (445-455))
In Development	Dual Ab rx of older adult Ph-ALL		M. Wieduwilt	M. Wieduwilt (455-505)
Active	FCR v ibrutinib in younger CLL	E1910	T. Shanafelt J. Barientos (A)	J. Barientos (505-510)
Active	Ibrutinib v ibrutinib/rituximab v bendamustine/rituximab in older adults with untreated CLL	A041202	J. Woyach	J Woyach (510-520))
In development	Successor study ideas to A041202, E1910		TBD	J. Byrd (520-535)
In development	Phase 3 study of FCR vs FCR + Ibrutinib for low risk IGHV mutated CLL < 70 yrs		J. Brown	J. Brown (535-545))
Active	Revlimid alone +/- Procrit in low or inter-1 risk MDS & symp anem	E2905	A. List	
In development	Potential MDS trial designs': MDS working group			T. Odenike (545-600)
In development	MDS prospective data/specimen gathering			T Al Bagdahdi (600-610)
Active	S1203: Rnd pIII for AML < 60: 1A & SAHA vs 1A vs 7+3 (DNR90)	CTSU	G. Garcia-Manero D. Rizzeri (A)	Notation only
In development	Status of Successor CBF AML Trial and S1203 successor	C10801 successor, S1203 successor	G. Marcucci, TBN	G. Marcucci, R Stone and others (610-635)

<b>In development</b>	Older adults with AML		G. Uy; H. Klepin	G. Uy; H. Klepin (635-650)
<b>Active</b>	Transplant Initiatives Relevant to Alliance			T Shea (650-700)
	<b>LEUKEMIA CORRELATIVE SCIENCES</b>			
<b>Active</b>	Molecular genetic features of acute leukemia	9862-02	W. Stock	
<b>Active</b>	Assessment of novel molecular markers in AML	20202-02	C. Bloomfield	
<b>Active</b>	Molecular markers of CLL	20203-00	J. Byrd	
<b>Active</b>	NK cell recognition & lysis of autologous blasts in AML pts	20206-00	D. Benson	
<b>Active</b>	LTB: MDR protein gene polymorphisms in AML	20501-01	M. Baer	
<b>Active</b>	LTB: Molecular genetic studies of AML with normal cytogenetics	20502-00	G. Marcucci	
	LTB: Identification of target genes for dx and prognosis of AML	20801-00	J. Rowley	